SCHEMBL5653653

SCHEMBL5653653

COc1ccc2nc(-c3ccc(C(=O)NCCCN4CCOCC4)cc3)[nH]c2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.58
FGFR2 P21802 1/20 0.58
FGFR3 P22607 1/20 0.58
KDR P35968 1/20 0.58
GAA P10253 2/20 0.56
TDP1 Q9NUW8 1/20 0.56
CYP2C9 P11712 2/20 0.55
CYP2D6 P10635 1/20 0.55
KMT2A Q03164 3/20 0.55
KDM4E B2RXH2 3/20 0.55
ALDH1A1 P00352 3/20 0.55
MEN1 O00255 2/20 0.55
HPGD P15428 2/20 0.55
CYP1A2 P05177 1/20 0.55
GLA P06280 1/20 0.55
CYP3A4 P08684 1/20 0.55
HSD17B10 Q99714 1/20 0.55
ACHE P22303 2/20 0.54
MAPT P10636 1/20 0.54
HDAC3 O15379 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5653663 0.93 KDM4E (0.57) FGFR1FGFR2FGFR3KDRGAA
SCHEMBL5651417 0.88 CYP2C9 (0.61) FGFR1FGFR2FGFR3KDRGAA
SCHEMBL5654261 0.88 FGFR1 (0.57) FGFR1FGFR2FGFR3KDRGAA
SCHEMBL5652713 0.88 FGFR1 (0.57) FGFR1FGFR2FGFR3KDRGAA
SCHEMBL5651930 0.88 FGFR1 (0.58) FGFR1FGFR2FGFR3KDRGAA
SCHEMBL5652001 0.87 KDM4E (0.58) CYP2D6KDM4EALDH1A1HPGDCYP1A2
SCHEMBL5650235 0.86 CYP2C9 (0.56) FGFR1FGFR2FGFR3KDRGAA
SCHEMBL5653799 0.85 CD274 (0.59) KDM4EALDH1A1HDAC3HDAC1HDAC2
SCHEMBL5650872 0.84 DRD3 (0.60) ALDH1A1MAPTCHEK2
SCHEMBL5650316 0.84 HDAC3 (0.54) KDM4EALDH1A1HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 FGFR1 1208/4885FGFR2 1535/4885FGFR3 1112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.